naxitamab
3 abstracts
Abstract
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine, Riley Hospital for Children,